Compositions and Methods Related to Flavivirus Envelope Protein Domain III Antigens
First Claim
Patent Images
1. A method of screening for a flavivirus in a subject or animal host comprising:
- a) contacting a sample from the subject or animal with a composition comprising a flavivirus envelope protein domain III polypeptide under conditions that permit formation of specific immunocomplex between an antibody in the sample and the envelope protein domain III polypeptide, wherein the envelope protein domain III polypeptide is a yellow fever virus envelope protein domain III polypeptide, West Nile virus envelope protein domain III polypeptide, St. Louis encephalitis virus envelope protein domain III polypeptide, Murray Valley encephalitis virus envelope protein domain III polypeptide, tick borne encephalitis serocomplex virus envelope protein domain III polypeptide or a combination thereof; and
b) detecting whether a specific immunocomplex is formed.
1 Assignment
0 Petitions
Accused Products
Abstract
The present invention concerns methods and compositions involving flavivirus envelope protein domain III antigens for the detection of virus and detection of antibodies against the virus. Such methods and compositions may be used to detect TBE serocomplex viruses or West Nile virus infection in a subject, patient, animal or biological fluid. The present invention also concerns kits for implementing such methods. In some embodiments, kits contain a recombinant TBE serocomplex virus or West Nile virus envelope protein domain III antigen.
101 Citations
43 Claims
-
1. A method of screening for a flavivirus in a subject or animal host comprising:
-
a) contacting a sample from the subject or animal with a composition comprising a flavivirus envelope protein domain III polypeptide under conditions that permit formation of specific immunocomplex between an antibody in the sample and the envelope protein domain III polypeptide, wherein the envelope protein domain III polypeptide is a yellow fever virus envelope protein domain III polypeptide, West Nile virus envelope protein domain III polypeptide, St. Louis encephalitis virus envelope protein domain III polypeptide, Murray Valley encephalitis virus envelope protein domain III polypeptide, tick borne encephalitis serocomplex virus envelope protein domain III polypeptide or a combination thereof; and b) detecting whether a specific immunocomplex is formed. - View Dependent Claims (3, 4, 5, 6, 10, 11, 12, 13, 19, 20)
-
-
2. (canceled)
-
7-8. -8. (canceled)
-
14-18. -18. (canceled)
- 21. A composition comprising an isolated West Nile virus or tick borne encephalitis serocomplex virus envelope protein domain III polypeptide.
-
24-25. -25. (canceled)
- 32. A kit for screening for flavivirus antibodies, in a suitable container means, comprising at least one envelope protein domain III polypeptide, wherein the at least one envelope protein domain III polypeptide is a yellow fever virus envelope protein domain III polypeptide, West Nile virus envelope protein domain III polypeptide, St. Louis encephalitis virus envelope protein domain III polypeptide, Murray Valley encephalitis virus envelope protein domain III polypeptide, a Central European encephalitis (CEE) virus envelope protein domain III polypeptide, a louping ill (LI) virus, a Russian spring-summer encephalitis (RSSE) virus envelope protein domain III polypeptide, a Langat (LGT) virus envelope protein domain III polypeptide, a Powassan virus (POW) envelope protein domain III polypeptide, an Alkhurma (ALK) envelope protein domain III polypeptide, a Kyasanur Forest disease (KFD) virus envelope protein domain III polypeptide, an Omsk hemorrhagic fever (OHF) virus envelope protein domain III polypeptide or a combination thereof.
-
33-40. -40. (canceled)
-
41. A kit for screening for West Nile virus antibodies or TBE serocomplex antibodies in a subject comprising:
-
a) an assay plate comprising a multiplicity of microtiter wells comprising a composition comprising at least one envelope protein domain III polypeptide capable of binding a flavivirus antibody in the sample that can specifically bind to at least one envelope protein domain III polypeptide; and b) a container means comprising a labeled secondary antibody having specific binding affinity for a flavivirus antibody in the sample that can specifically bind to at least one envelope protein domain III polypeptide.
-
-
42. (canceled)
Specification